AGP Executive Report
Last update: 8 hours agoPTSD Nightmares, THC/CBD: Charité researchers report in Nature Medicine that a prescription THC-containing treatment helped more than half of PTSD patients, with over a third seeing nightmares fully disappear. Dementia Agitation Trial: A Kentucky Phase 2 LIBBY study is testing an oil-based THC/CBD combo for agitation in advanced dementia patients. Obesity Drug Update: Corbus says the last patient completed Phase 1b CANYON-1 for CRB-913, an oral CB1-targeting cannabinoid designed to limit brain penetration. Hemp/THC Crackdowns (Texas + NC): Texas bans several hemp-derived THC products (including Delta-8/10 and THCA flower), creating confusion and legal risk for consumers and retailers; in North Carolina, HB 328 faces backlash and was tabled until November after protests and industry warnings it could wipe out most products. Access Shifts (Georgia): Georgia’s medical cannabis registry jumped 22% after lawmakers eased access rules. Industry Pressure (Federal): Cornbread Hemp warns a federal ban could devastate the hemp market, while state AGs push Congress to keep protections for intoxicating-hemp consumers. Workplace/Policy: A Southeast ADA Center explainer highlights how medical marijuana intersects with disability rights in jobs, housing, and healthcare.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
